Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

BMS Adds New NASH Drug to its Portfolio

By Ryan Bushey | November 10, 2016

Bristol-Myers Squibb has acquired the rights to an early-stage drug candidate targeting liver fibrosis that occurs as a result of nonalcoholic steatohepatitis (NASH).

The biotech company will pay $100 million upfront to Japan’s Nitto Denko who developed this drug.

Nitto will be able to receive a number of clinical and regulatory milestone payments and royalties under the deal, reported Reuters. BMS will also have the ability to option exclusive licensing rights for other drugs Nitto is working on for potentially treating lung fibrosis and similar conditions.

The drug BMS is incorporating into its portfolio is a siRNA inhibitor designed to inhibit heat shock protein 47, explained Endpoints News. The hope is that the drug attacking this protein may impede the production of collagen that plays a part in the formation of fibrosis and NASH.

Investigators are currently running a Phase 1b study to track how this drug could perform that action on patients over the course of 5 weeks.

Mergers and acquisition deals have been particularly active in the NASH space over the past few months.

Allergan acquired a slew of companies specializing in this type of drug development. Gilead reported promising data for a NASH candidate that lead to mixed but well tolerated results in improving liver fibrosis as well.

An analysis published by Thompson Reuters in February noted this development area could yield over $1 billion in sales for companies who create a potent drug.  


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50